Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the malignancy derived from normal hepatocytes with increasing incidence and extremely poor prognosis worldwide. The only approved first‐line systematic treatment agent for HCC, sorafenib, is capable to effectively improve advanced HCC patients’ survival. However, i...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Med
Main Authors: Dai, Jimin, Huang, Qichao, Niu, Kunwei, Wang, Bo, Li, Yijie, Dai, Chen, Chen, Zhinan, Tao, Kaishan, Dai, Jingyao
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2018
Subjects:
Cancer Biology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6247041/
https://ncbi.nlm.nih.gov/pubmed/30311444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1826
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items